Home - Products - Daptomycin RT vials

Daptomycin RT vials

Daptomycin is a lipopeptide antibacterial agent active against gram-positive bacteria.

Indication: Used in the treatment of complicated skin and skin structure/soft-tissue infections caused by susceptible isolates of gram-positive bacteria such as Staphylococcus aureus (including MRSA-methicillin-resistant Staphylococcus aureus), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae supsp. equisimilis and Enterococcus faecalis (vancomycin-susceptible isolates only).

Additionally used for bloodstream infections (bacteremia), including patients with right-sided infective endocarditis caused by Staphylococcus aureus.

Application: Administered as intravenous infusions or injections.

Dosage form

Lyophilized vials


350 mg

500 mg


No monograph for daptomycin in either Ph. Eur. or USP available

Manufacturing site

CMO for Xellia Pharmaceuticals ApS

Release site

CMO for Xellia Pharmaceuticals ApS

Xellia Pharmaceuticals ApS, Copenhagen, Denmark

Site registered

EU GMP issued by Danish Medicines Agency


Other health authorities

Batch size

350 mg


40789 vials

42592 vials

Regulatory documentation

EU dossier (filing Q1, 2024)

US dossier

Packaging sizes

1 vial/pack

Shelf life

24 months

Storage conditions

EU dossier: Store below 25°C (77°F)
US dossier: Between 20-25°C (68-77°F)